TY  - INPR
SN  - 2666-5247
PB  - Elsevier BV
UR  - https://doi.org/10.1016/j.lanmic.2025.101117
ID  - discovery10206194
A1  - Yates, Tom A
A1  - Grint, Daniel J
JF  - The Lancet Microbe
AV  - public
Y1  - 2025/03/15/
TI  - Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes
N1  - Copyright © 2025 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/
4.0/).
ER  -